Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Other 3Sarcoma 1Plasma cell 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Mucositis 3Hematologic Neoplasms 3Graft vs Host Disease 1

Interventions

Radiotherapy 5Surveys and Questionnaires 4Cisplatin 4angiotensin I (1-7) 3alvimopan 3Radiation 3Injections 3Water 2Vitamin D 2Tirzepatide 2RRx-001 2Mouthwashes 2Metformin 2Interleukin 1 Receptor Antagonist Protein 2High-Intensity Focused Ultrasound Ablation 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Calcium Dobesilate 2Amifostine 2Acetylcysteine 2tempol 1peppermint oil 1pegfilgrastim 1naloxegol 1methylnaltrexone 1methyl N-acetylsibirosaminide 1linaclotide 1licogliflozin 1kang-lai-te 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × angiotensin I (1-7) × Other × Clear all
NCT01554254 2016-08-31

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882374 2016-08-31

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡